Louis Potters

Summary

Publications

  1. ncbi A chronological database to support outcomes research in prostate cancer
    Louis Potters
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, New York 11570, USA
    Int J Radiat Oncol Biol Phys 56:1252-8. 2003
  2. ncbi Permanent prostate brachytherapy in men with clinically localised prostate cancer
    L Potters
    Department of Radiation Oncology, Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York 11570, USA
    Clin Oncol (R Coll Radiol) 15:301-15. 2003
  3. ncbi Toward a dynamic real-time intraoperative permanent prostate brachytherapy methodology
    Louis Potters
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, NY, USA
    Brachytherapy 2:172-80. 2003
  4. ncbi 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer
    Louis Potters
    New York Prostate Institute at South Nassau Communities Hospital, Oceanside, New York 11572, USA
    J Urol 173:1562-6. 2005
  5. ncbi Is there a role for postimplant dosimetry after real-time dynamic permanent prostate brachytherapy?
    Louis Potters
    New York Prostate Institute, South Nassau Communities Hospital, Oceanside, NY 11572, USA
    Int J Radiat Oncol Biol Phys 65:1014-9. 2006
  6. ncbi Stereotactic body radiation therapy
    Louis Potters
    South Nassau Communities Hospital, Oceanside, New York 11572, USA
    J Am Coll Radiol 2:676-80. 2005
  7. ncbi Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation
    Michael J Zelefsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 67:327-33. 2007
  8. ncbi The effect of isotope selection on the prostate-specific antigen response in patients treated with permanent prostate brachytherapy
    Louis Potters
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, NY 11570, USA
    Brachytherapy 2:26-31. 2003
  9. ncbi Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy
    Nelson N Stone
    Mount Sinai School of Medicine, New York, NY, USA
    Int J Radiat Oncol Biol Phys 73:341-6. 2009
  10. ncbi Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes
    Nelson N Stone
    Mount Sinai School of Medicine, New York, NY, USA
    Int J Radiat Oncol Biol Phys 69:1472-7. 2007

Detail Information

Publications38

  1. ncbi A chronological database to support outcomes research in prostate cancer
    Louis Potters
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, New York 11570, USA
    Int J Radiat Oncol Biol Phys 56:1252-8. 2003
    ..To outline the process for developing a data management system for patients with prostate cancer...
  2. ncbi Permanent prostate brachytherapy in men with clinically localised prostate cancer
    L Potters
    Department of Radiation Oncology, Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York 11570, USA
    Clin Oncol (R Coll Radiol) 15:301-15. 2003
    ..Treatment planning techniques that use new treatment planning computers may assist in improving the implant procedure and dosimetry and are now available...
  3. ncbi Toward a dynamic real-time intraoperative permanent prostate brachytherapy methodology
    Louis Potters
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, NY, USA
    Brachytherapy 2:172-80. 2003
    ..To evaluate dosimetry and source location relative to CT-based dosimetry when performing real-time dynamic permanent prostate brachytherapy (PPB) with inverse treatment planning...
  4. ncbi 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer
    Louis Potters
    New York Prostate Institute at South Nassau Communities Hospital, Oceanside, New York 11572, USA
    J Urol 173:1562-6. 2005
    ..We reviewed the outcomes in men treated with permanent prostate brachytherapy (PPB)...
  5. ncbi Is there a role for postimplant dosimetry after real-time dynamic permanent prostate brachytherapy?
    Louis Potters
    New York Prostate Institute, South Nassau Communities Hospital, Oceanside, NY 11572, USA
    Int J Radiat Oncol Biol Phys 65:1014-9. 2006
    ..To evaluate the correlation of real-time dynamic prostate brachytherapy (RTDPB) dosimetry and traditional postimplant dosimetry for permanent prostate brachytherapy...
  6. ncbi Stereotactic body radiation therapy
    Louis Potters
    South Nassau Communities Hospital, Oceanside, New York 11572, USA
    J Am Coll Radiol 2:676-80. 2005
    ..This review summarizes the state of stereotactic body radiation in 2005...
  7. ncbi Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation
    Michael J Zelefsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 67:327-33. 2007
    ..To assess long-term prostate-specific antigen (PSA) outcome after permanent prostate brachytherapy (BT) and identify predictors of improved disease-free survival...
  8. ncbi The effect of isotope selection on the prostate-specific antigen response in patients treated with permanent prostate brachytherapy
    Louis Potters
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, NY 11570, USA
    Brachytherapy 2:26-31. 2003
    ..To assess the difference in prostate-specific antigen (PSA) response kinetics in patients undergoing either (125)I or (103)Pd permanent prostate brachytherapy (PPB)...
  9. ncbi Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy
    Nelson N Stone
    Mount Sinai School of Medicine, New York, NY, USA
    Int J Radiat Oncol Biol Phys 73:341-6. 2009
    ..To investigate the biochemical control rates and survival for Gleason score 7-10 prostate cancer patients undergoing permanent prostate brachytherapy as a function of the biologic effective dose (BED)...
  10. ncbi Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes
    Nelson N Stone
    Mount Sinai School of Medicine, New York, NY, USA
    Int J Radiat Oncol Biol Phys 69:1472-7. 2007
    ..To investigate the biochemical control rate in patients undergoing permanent prostate brachytherapy as a function of the biologically effective dose (BED) and risk group...
  11. ncbi Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation
    Louis Potters
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, NY, USA
    Radiother Oncol 71:29-33. 2004
    ....
  12. ncbi Importance of implant dosimetry for patients undergoing prostate brachytherapy
    Louis Potters
    Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center at Mercy Medical Center, Rockville Centre, New York, USA
    Urology 62:1073-7. 2003
    ..Overall, the reported 10-year BFR rates in this study were favorable. Strategies for ensuring the best quality implant should be used and, when reporting brachytherapy outcomes, the implant quality should be noted...
  13. ncbi The prognostic significance of Gleason Grade in patients treated with permanent prostate brachytherapy
    Louis Potters
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, NY 11570, USA
    Int J Radiat Oncol Biol Phys 56:749-54. 2003
    ..To assess the difference in biochemical freedom from relapse (BFR) between patients with clinically localized prostate cancer having Gleason Grade (GG) 3 + 4 vs. 4 + 3 disease treated with permanent prostate brachytherapy (PPB)...
  14. ncbi Prognostic significance of race on biochemical control in patients with localized prostate cancer treated with permanent brachytherapy: multivariate and matched-pair analyses
    Lucille N Lee
    Department of Radiation Oncology, Memorial Sloan-Kettering at Mercy Medical Center, Rockville Center, NY 11570, USA
    Int J Radiat Oncol Biol Phys 53:282-9. 2002
    ..This result is consistent with other studies that also show that race does not contribute to differences in outcome after definitive therapies for localized prostate cancer...
  15. ncbi American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy
    Brian J Davis
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Brachytherapy 11:6-19. 2012
    ..To provide updated American Brachytherapy Society (ABS) guidelines for transrectal ultrasound-guided transperineal interstitial permanent prostate brachytherapy (PPB)...
  16. ncbi Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer
    Patrick A Kupelian
    Department of Radiation Oncology, M D Anderson Cancer Center Orlando, Orlando, FL 32806, USA
    Int J Radiat Oncol Biol Phys 58:25-33. 2004
    ....
  17. ncbi Comparison of biochemical failure definitions for permanent prostate brachytherapy
    Deborah A Kuban
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 65:1487-93. 2006
    ..To assess prostate-specific antigen (PSA) failure definitions for patients with Stage T1-T2 prostate cancer treated by permanent prostate brachytherapy...
  18. ncbi A comprehensive and novel predictive modeling technique using detailed pathology factors in men with localized prostate carcinoma
    Louis Potters
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, New York 11570, USA
    Cancer 95:1451-6. 2002
    ....
  19. ncbi External radiotherapy and permanent prostate brachytherapy in patients with localized prostate cancer
    Louis Potters
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, NY 11570, USA
    Brachytherapy 1:36-41. 2002
    ..Cox regression failed to identify an improvement in PSA-FFR with RT-PPB or the addition of hormones. Although these conclusions question the role for RT-PPB, only a comparative trial will be able to answer this question definitively...
  20. ncbi Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States
    Steven J Frank
    Department of Radiation Oncology, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Brachytherapy 6:2-8. 2007
    ..This study is aimed at understanding and defining the current patterns of care with respect to prostate brachytherapy for patients with intermediate-risk localized disease in the combined academic and community setting...
  21. ncbi Impact of intraoperative edema during transperineal permanent prostate brachytherapy on computer-optimized and preimplant planning techniques
    Yoshiya Yamada
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Clin Oncol 26:e130-5. 2003
    ..Preplanned patients who encountered a greater degree of intraoperative edema had less %D90 target coverage...
  22. ncbi Assessment of external beam radiation technology for dose escalation and normal tissue protection in the treatment of prostate cancer
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 70:671-7. 2008
  23. ncbi Nomograms for clinically localized prostate cancer. Part II: radiation therapy
    Louis Potters
    Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center at Mercy Medical Center, Rockville Center, NY 11570, USA
    Semin Urol Oncol 20:131-9. 2002
    ....
  24. ncbi American Society for Therapeutic Radiology and Oncology and American College of Radiology practice guideline for the performance of stereotactic body radiation therapy
    Louis Potters
    Department of Radiation Oncology, South Nassau Communities Hospital, Oceanside, NY, USA
    Int J Radiat Oncol Biol Phys 60:1026-32. 2004
  25. ncbi Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy
    L Potters
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, NY 11570, USA
    J Clin Oncol 18:1187-92. 2000
    ..To assess the role of neoadjuvant androgen deprivation (NAAD) and transperineal interstitial permanent prostate brachytherapy (TIPPB) using a matched-pair analysis selected from a large cohort of patients undergoing TIPPB...
  26. ncbi Permanent prostate brachytherapy: lessons learned, lessons to learn
    L Potters
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Oncology (Williston Park) 14:981-91; discussion 991-2, 997-9. 2000
    ..Treatment planning techniques that utilize new imaging modalities, coupled with computerized treatment planning, may help improve the implant procedure and dosimetry...
  27. ncbi A theoretical derivation of the nomograms for permanent prostate brachytherapy
    X H Wang
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, New York 11570, USA
    Med Phys 28:683-7. 2001
    ..Thus in theory, use of lower activity seeds will require less total activity to deliver a prescribed dose. Based on our study, Pd-103 delivers a higher therapeutic ratio and a lower integral dose to the patient compared to I-125...
  28. ncbi Urinary morbidity following ultrasound-guided transperineal prostate seed implantation
    D Y Gelblum
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, NY 11570, USA
    Int J Radiat Oncol Biol Phys 45:59-67. 1999
    ..To assess the urinary morbidity experienced by patients undergoing ultrasound-guided, permanent transperineal seed implantation for adenocarcinoma of the prostate...
  29. ncbi A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy
    L Potters
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, New York 11570, USA
    Int J Radiat Oncol Biol Phys 50:605-14. 2001
    ..This study was undertaken to assess the recommended dosimetry parameters from a large cohort of patients undergoing TIPPB that would predict for PSA relapse-free survival (PSA-RFS)...
  30. ncbi The role of external radiotherapy in patients treated with permanent prostate brachytherapy
    L Potters
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, NY 11570, USA
    Prostate Cancer Prostatic Dis 5:47-53. 2002
    ..A matched pair analysis performed also failed to identify any significant difference based on treatment modality...
  31. ncbi Potency after permanent prostate brachytherapy for localized prostate cancer
    L Potters
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Center, NY 11570, USA
    Int J Radiat Oncol Biol Phys 50:1235-42. 2001
    ..The evaluation of potency preservation after treatment of localized prostate cancer with transperineal permanent prostate brachytherapy (PPB) and the efficacy of sildenafil were studied...
  32. ncbi Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer
    D Y Gelblum
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Center, New York, NY 11570, USA
    Int J Radiat Oncol Biol Phys 48:119-24. 2000
    ..This clinical report documents rectal toxicity from a large cohort of men treated by a single practitioner for adenocarcinoma of the prostate...
  33. ncbi Critical organ dosimetry in permanent seed prostate brachytherapy: defining the organs at risk
    Juanita M Crook
    Department of Radiation Oncology, Princess Margaret Hospital, Toronto, Canada
    Brachytherapy 4:186-94. 2005
    ..We set out to examine the existing data and propose a uniform method of reporting such that results from different centers can more easily be compared...
  34. ncbi Dynamic dose-feedback prostate brachytherapy in patients with large prostates and/or planned transurethral surgery before implantation
    Peter L Acher
    Guy s and St Thomas NHS Foundation Trust, London, UK
    BJU Int 99:1066-71. 2007
    ....
  35. ncbi Permanent prostate brachytherapy: Dosimetric results and analysis of a learning curve with a dynamic dose-feedback technique
    Peter Acher
    Department of Urology, Guy s and St Thomas NHS Foundation Trust, London, UK
    Int J Radiat Oncol Biol Phys 65:694-8. 2006
    ..The purpose of this study is to assess the dosimetric learning curve associated with this approach...
  36. ncbi The art of radiation oncology?
    Louis Potters
    Int J Radiat Oncol Biol Phys 68:966-7. 2007
  37. ncbi Practice guideline for the performance of therapy with unsealed radiopharmaceutical sources
    Gary L Dillehay
    American College of Radiology, Reston, VA, USA
    Int J Radiat Oncol Biol Phys 64:1299-307. 2006
  38. ncbi A multicenter study demonstrating discordant results from electronic prostate-specific antigen biochemical failure calculation systems
    Scott G Williams
    Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia
    Int J Radiat Oncol Biol Phys 65:1494-500. 2006
    ..To evaluate the interobserver variation of four electronic biochemical failure (bF) calculators using three bF definitions...